We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
Read MoreHide Full Article
Enovis Corporation (ENOV - Free Report) recently closed its earlier-announced acquisition of privately-held LimaCorporate S.p.A. (Lima). The buyout is expected to add Lima’s complementary surgical solutions and customers to Enovis’ Reconstructive portfolio.
The buyout was initially announced in September 2023.
The latest acquisition is expected to significantly boost Enovis’ Reconstructive portfolio and provide it with the opportunity to expand its global presence.
Rationale Behind the Acquisition
Per Enovis, the latest buyout will likely strengthen its position in the global orthopedic reconstruction market with a complementary portfolio of surgical solutions and technologies. This, in turn, is expected to accelerate global growth and margin expansion for Enovis.
Lima's portfolio includes 3D-printed Trabecular Titanium implants and a comprehensive revision offering for shoulders. This is expected to further strengthen Enovis’ position in the fast-growing extremities market.
Enovis’ management commented that the buyout will likely establish an orthopedic reconstruction business worth approximately $1 billion, with approximately 50% of revenues in the fast-growing extremities markets.
Financial Implications
Enovis believes that the acquisition will likely create robust cross-selling opportunities and approximately $40 million in cost synergies to be fully realized by the third year after closing via supply-chain optimization and cost consolidation. Management also believes that the buyout would support Enovis’ long-term goals of high-single-digit organic revenue growth and sustainable EBITDA margin expansion.
Enovis expects Lima to generate sales of $290-$300 million and $70-$75 million of adjusted EBITDA in 2024.
Industry Prospects
Per a report by Data Bridge Market Research, the global orthopedic joint reconstruction market was valued at $17.77 billion in 2021 and is anticipated to reach $24.13 billion by 2029 at a CAGR of 3.9%. Factors like technological advancement in the orthopedic joint reconstruction sector, focus on developing surgical robots, and a rise in research and development activities are expected to drive the market.
Given the market potential, the recent acquisition is expected to provide a significant impetus to Enovis’ business globally.
Notable Developments
In November 2023, Enovis announced its third-quarter 2023 results, wherein it registered a robust uptick in its overall net sales, including strong organic sales per day growth. Sales in the Reconstructive segment were strong both on a reported and organic basis.
In October, Enovis announced its plans to showcase the latest technologies from its Surgical business at the American Association of Hip and Knee Surgeons annual meeting between Nov 2 and 5, 2023. The items displayed included an updated ARVIS Augmented Reality System, EMPOWR blade stem and EMPOWR 3D Knee.
Price Performance
Shares of the company have lost 2.7% in the past year compared with the industry’s 9.7% decline. The S&P 500 has witnessed 24.4% growth in the said time frame.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, Enovis Medical carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 17.3%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 36.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 34.1% compared with the industry’s 9.1% rise in the past year.
Merit Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 11.5%. MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average being 14.4%.
Merit Medical has gained 6.2% compared with the industry’s 11.7% rise in the past year.
Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.9%.
Integer Holdings’ shares have rallied 41.2% against the industry’s 0.5% decline in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
Enovis Corporation (ENOV - Free Report) recently closed its earlier-announced acquisition of privately-held LimaCorporate S.p.A. (Lima). The buyout is expected to add Lima’s complementary surgical solutions and customers to Enovis’ Reconstructive portfolio.
The buyout was initially announced in September 2023.
The latest acquisition is expected to significantly boost Enovis’ Reconstructive portfolio and provide it with the opportunity to expand its global presence.
Rationale Behind the Acquisition
Per Enovis, the latest buyout will likely strengthen its position in the global orthopedic reconstruction market with a complementary portfolio of surgical solutions and technologies. This, in turn, is expected to accelerate global growth and margin expansion for Enovis.
Lima's portfolio includes 3D-printed Trabecular Titanium implants and a comprehensive revision offering for shoulders. This is expected to further strengthen Enovis’ position in the fast-growing extremities market.
Enovis’ management commented that the buyout will likely establish an orthopedic reconstruction business worth approximately $1 billion, with approximately 50% of revenues in the fast-growing extremities markets.
Financial Implications
Enovis believes that the acquisition will likely create robust cross-selling opportunities and approximately $40 million in cost synergies to be fully realized by the third year after closing via supply-chain optimization and cost consolidation. Management also believes that the buyout would support Enovis’ long-term goals of high-single-digit organic revenue growth and sustainable EBITDA margin expansion.
Enovis expects Lima to generate sales of $290-$300 million and $70-$75 million of adjusted EBITDA in 2024.
Industry Prospects
Per a report by Data Bridge Market Research, the global orthopedic joint reconstruction market was valued at $17.77 billion in 2021 and is anticipated to reach $24.13 billion by 2029 at a CAGR of 3.9%. Factors like technological advancement in the orthopedic joint reconstruction sector, focus on developing surgical robots, and a rise in research and development activities are expected to drive the market.
Given the market potential, the recent acquisition is expected to provide a significant impetus to Enovis’ business globally.
Notable Developments
In November 2023, Enovis announced its third-quarter 2023 results, wherein it registered a robust uptick in its overall net sales, including strong organic sales per day growth. Sales in the Reconstructive segment were strong both on a reported and organic basis.
In October, Enovis announced its plans to showcase the latest technologies from its Surgical business at the American Association of Hip and Knee Surgeons annual meeting between Nov 2 and 5, 2023. The items displayed included an updated ARVIS Augmented Reality System, EMPOWR blade stem and EMPOWR 3D Knee.
Price Performance
Shares of the company have lost 2.7% in the past year compared with the industry’s 9.7% decline. The S&P 500 has witnessed 24.4% growth in the said time frame.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, Enovis Medical carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 17.3%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 36.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 34.1% compared with the industry’s 9.1% rise in the past year.
Merit Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 11.5%. MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average being 14.4%.
Merit Medical has gained 6.2% compared with the industry’s 11.7% rise in the past year.
Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.9%.
Integer Holdings’ shares have rallied 41.2% against the industry’s 0.5% decline in the past year.